Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ITabMed Formed as JV to Develop T Cell Engagers; Raises $20 Million

publication date: Dec 1, 2021

Shanghai ITabMed announced it has completed the spin-off from Evive Biotech of the iTAb™ (immunotherapy antibody) platform and closed a $20 million Series A-round financing. Earlier this year, Evive (formerly Generon BioMed) and Dr. Xiaoqiang Yan formed ITabMed as a joint venture with full support from Evive. The JV will focus on continued development of oncology immunotherapies derived from the iTAb™ platform, which generates bi- or tri-specific T cell engagers. The company has started Phase I trials of two products while other iTAb drug candidates are in preclinical development. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital